Cantor Fitzgerald Reiterates Overweight Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $60.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the company’s current price. Other […]

Related Keywords

Robertw Baird , ,Longboard Pharmaceuticals Stock Performance ,Longboard Pharmaceuticals ,Parkman Healthcare Partners ,Longboard Pharmaceuticals Company Profile ,Td Asset Management Inc ,Cantor Fitzgerald ,Analyst Recommendations For Longboard Pharmaceuticals ,Bourgeon Capital Management ,News Ratings For Longboard Pharmaceuticals Daily ,Denali Advisors ,Citigroup ,Longboard Pharmaceuticals Inc ,Asset Management Inc ,Hedge Funds Weigh In On Longboard Pharmaceuticals ,Get Free Report ,Capital Management ,Management Inc ,Healthcare Partners ,Longboard Pharmaceuticals Daily ,Nasdaq Lbph ,Lbph ,Medical ,Reiterated Rating ,